Predicted-positive patients also had poorer metastasis-free survival (hazard ratios [HR] = 1.92, design-set; HR = 2.05, test-set).
We analyze treatment success in terms of survival hazard ratio as a function of the network structures.
To test this hypothesis, we plotted the average value of survival hazard ratio for nodes as a function of their connectivity (degree).
In this work, we choose the survival hazard ratio (HR), as reported in each RCT, as the crucial metric of treatment success.
That is, successful trials are considered as those with a statistically significant survival hazard ratio with value greater than 1 (at p value ≤0.05).
The interaction decreased the survival hazard among African-American women and increased the survival hazard among Caucasian women.
MMP8 is prognostic as a continuous variable for relapse-free survival (hazard ratio = 0.76, P = 0.045) and for overall survival (hazard ratio = 0.69, P = 0.025).
Ibrutinib also significantly prolonged overall survival (hazard ratio, 0.43, P=0.005).
However, Black African women had significantly worse overall survival (hazard ratio 1.24, P=0.025).
Adherence <80% was associated with poorer survival, hazard ratio 1.10, 95% CI=1.001 1.21.
No significant difference in survival hazard was found between the two groups (P = 0.19).
